Abstract:BackgroundWe previously reported initial Phase 2 study results for 60 gout patients treated with SEL-212, a novel combination treatment comprised of pegsiticase (pegylated uricase) co-administered with a synthetic vaccine particle encapsulating rapamycin (SVP-R).1 SEL-212 was well-tolerated, mitigated the formation of anti-drug antibodies, and enabled sustained control of serum uric acid (sUA) levels in most subjects.1 In this ongoing study, new treatment cohorts involving higher SVP-R dose levels and extended… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.